TheraRadar
Clinical-Stage Companies / ALK-Abelló

ALK-Abelló

Pre-Approval PRO BETA
41
Total Trials
23
Phase 3
20
Phase 2
2
Recruiting
516
Score

Pipeline by Phase

Phase 3
23
Phase 2
20
Phase 1
2

Therapeutic Focus

Allergic Rhinoconjunctivitis Allergic Rhinitis Allergy Conjunctivitis Rhinitis, Allergic, Perennial

Clinical Trials (41)

NCT07060885 Phase 3 RECRUITING

A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65

Started: 9/1/2025

NCT04878354 Phase 3 COMPLETED

A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis

Started: 4/7/2021

NCT04881461 Phase 3 COMPLETED

A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis

Started: 5/10/2021

NCT04145219 Phase 3 COMPLETED

House Dust Mite Allergy Trial In Children

Started: 10/12/2019

NCT03654976 Phase 3 COMPLETED

Mite Asthma Pediatric Immunotherapy Trial

Started: 2/22/2018

NCT04541004 Phase 3 COMPLETED

Adolescent Mite Allergy Safety Evaluation

Started: 9/23/2020

NCT04176185 Phase 3 TERMINATED

A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber

Started: 11/4/2019

NCT01700192 Phase 3 COMPLETED

Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

Started: 1/1/2013

NCT01385371 Phase 3 COMPLETED

A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)

Started: 6/1/2011

NCT01469182 Phase 3 COMPLETED

A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

Started: 11/1/2011

NCT01433523 Phase 3 COMPLETED

House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma

Started: 8/1/2011

NCT01454544 Phase 3 COMPLETED

A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet

Started: 10/1/2011

NCT01061203 Phase 3 COMPLETED

Grazax Asthma Prevention

Started: 1/1/2010

NCT01603056 Phase 3 COMPLETED

Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis

Started: 10/1/2009

NCT00807547 Phase 3 COMPLETED

Intraseasonal Short-time Up-dosing With Alutard SQ Grasses

Started: 4/1/2008

NCT01740284 Phase 3 COMPLETED

A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine

Started: 9/1/2008

NCT00773240 Phase 3 COMPLETED

A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment

Started: 4/1/2008

NCT01644617 Phase 2 COMPLETED

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

Started: 10/1/2012

NCT00978029 Phase 2 COMPLETED

Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

Started: 11/1/2009

NCT00770315 Phase 2 COMPLETED

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)

Started: 9/1/2009

NCT00783198 Phase 2 COMPLETED

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)

Started: 9/1/2009

NCT02481856 Phase 2 COMPLETED

A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber

Started: 6/1/2015

NCT02166268 Phase 2 COMPLETED

Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber

Started: 6/1/2014

NCT01425788 Phase 2 COMPLETED

Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense

Started: 8/1/2011

NCT01454531 Phase 2 COMPLETED

An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy

Started: 6/1/2011

NCT02065856 Phase 2 COMPLETED

An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy

Started: 12/1/2013

NCT01568190 Phase 2 COMPLETED

An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy

Started: 12/1/2011

NCT02069535 Phase 2 COMPLETED

An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy

Started: 4/1/2014

NCT01728298 Phase 2 COMPLETED

A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy

Started: 11/1/2012

NCT01438827 Phase 2 COMPLETED

Avanz Phleum Pratense Maintenance Dose

Started: 9/1/2011

NCT01675791 Phase 2 COMPLETED

A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet

Started: 8/1/2012

NCT01674595 Phase 2 COMPLETED

An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy

Started: 9/1/2012

NCT01191359 Phase 2 COMPLETED

Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch

Started: 1/1/2010

NCT00857779 Phase 2 COMPLETED

Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients

Started: 2/1/2009

NCT01240954 Phase 2 TERMINATED

Comparison of Different Up-dosing Schedules With Osiris

Started: 12/1/2010

NCT00987909 Phase 2 COMPLETED

Exposure Chamber Trial With Cat Immunotherapy

Started: 9/1/2009

NCT05440643 Phase 1 ACTIVE NOT RECRUITING

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Started: 9/7/2022

NCT01678807 Phase 1 COMPLETED

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

Started: 10/1/2012

NCT02437786 Phase 4 COMPLETED

Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

Started: 9/1/2009

NCT01854736 Phase 4 COMPLETED

Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate

Started: 4/1/2013

NCT02256553 Phase 4 COMPLETED

Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)

Started: 10/1/2014

Drug Candidates

Peanut SLIT-tablet HDM SLIT-tablet (12 SQ-HDM) Tree SLIT-tablet Placebo SLIT-tablet 5-grass mix SLIT-drops Placebo Sublingual allergy immunotherapy tablet HDM SLIT-tablet Sublingual allergy immunological tablet GRAZAX
Activity Status: Active
Last Trial Started: 9/1/2025
Last Trial Ended: 9/26/2023
Trials (12 months): 1
Completed Trials: 37
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.